Acute Myeloid Leukemia Pipeline Analysis 2026: Highlights 100+ Companies and 110+ Drug Candidates
Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Acute Myeloid Leukemia (AML) - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.
The report provides a comprehensive global assessment of the Acute Myeloid Leukemia (AML) pipeline, covering more than 100 companies and over 110 investigational therapies. It evaluates clinical and nonclinical candidates by development stage, product type, route of administration and molecule type, while also examining discontinued and inactive programs.
AML is a rapidly progressing myeloid neoplasm characterized by clonal expansion of immature myeloid-derived blasts in peripheral blood and bone marrow. Disease progression can result in ineffective erythropoiesis and megakaryopoiesis, cytopenias and bone marrow failure. AML may also arise following myeloproliferative neoplasms, myelodysplastic syndromes, aplastic anemia and other antecedent hematologic conditions.
Diagnostic evaluation may include peripheral blood and bone marrow assessment, cytogenetic analysis, molecular profiling and laboratory testing for markers associated with high tumor burden and rapid cellular turnover. Risk-adapted AML treatment can incorporate intensive cytotoxic chemotherapy, molecularly targeted agents and hematopoietic stem cell transplantation. Induction therapy is intended to achieve complete remission, followed by consolidation strategies designed to address measurable residual disease and reduce relapse risk.
Acute Myeloid Leukemia Pipeline Scope
The report combines scientific, clinical and commercial analysis of emerging AML therapies. Individual pipeline profiles include mechanism of action, clinical trial activity, regulatory progress and product development milestones. Coverage also extends to collaborations, licensing agreements, mergers and acquisitions, funding, regulatory designations and other strategic developments influencing the Acute Myeloid Leukemia treatment landscape.
Pipeline candidates are assessed across Phase III, Phase II, Phase I, pre-clinical and discovery stages. The analysis also segments products by oral, intravenous, subcutaneous, parenteral and topical routes of administration. Molecule categories include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers and gene therapies. Product strategies are classified as monotherapy, combination therapy or candidates being evaluated in both settings.
Selected Emerging Acute Myeloid Leukemia Drugs
Other products covered include Clifutinib, BL-M11D1, Tagraxofusp, Cusatuzumab, QHRD-107, DFP-10917, MEN1703, Debio-1562M, AK-117, AZD-3632, MB-dNPM1-TCR.1, AB-8939, CTX-712, MP-0533, GDX-012, ARD-103 and GB3226.
Companies Advancing AML Research and Development
The competitive landscape includes Johnson & Johnson, Orca Biosystems, Inc., Ryvu Therapeutics, Advanced BioDesign, CERo Therapeutics Holdings, Inc., Promicell INC., Sunshine Lake Pharma, Sichuan Baili Pharmaceutical, Stemline Therapeutics, OncoVerity, Delta-Fly Pharma, Menarini, Debiopharm International SA, Akeso Biopharma, AstraZeneca, Miltenyi Biomedicine GmbH, AB Science, Chordia Therapeutics, Molecular Partners AG, Takeda, ARCE Therapeutics, Galecto Biotech AB, Shenzhen TargetRx Co., Ltd., CRISPR Therapeutics and Lomond Therapeutics.
Strategic Insights and Key Questions
The report examines unmet needs, emerging treatment trends, novel technologies and the anticipated impact of investigational therapies on the AML market. It evaluates how many companies and products are active at each stage of development, which candidates have reached mid-stage or late-stage trials and what regulatory designations have been granted.
Additional analysis addresses current AML clinical studies, development status, Industry-Industry and Industry-Academia collaborations, licensing transactions, mergers and acquisitions. These insights support pharmaceutical companies, biotechnology organizations, investors, researchers and other stakeholders seeking to understand competitive positioning and future opportunities within the global Acute Myeloid Leukemia pipeline.
Key Topics Covered:
Introduction
Executive Summary
Acute Myeloid Leukemia (AML): Overview
Pipeline Therapeutics
Therapeutic Assessment
Acute Myeloid Leukemia (AML)- Analytical Perspective
Late Stage Products (Preregistration)
Orca-T: Orca Biosystems, Inc
Mid Stage Products (Phase II)
Romaciclib: Ryvu Therapeutics
Early Stage Products (Phase I)
CER-1236: CERo Therapeutics Holdings, Inc.
Preclinical and Discovery Stage Products
PRO CAR-301: Promicell INC.
Inactive Products
Acute Myeloid Leukemia (AML) Key Companies
Acute Myeloid Leukemia (AML) Key Products
Acute Myeloid Leukemia (AML)- Unmet Needs
Acute Myeloid Leukemia (AML)- Market Drivers and Barriers
Acute Myeloid Leukemia (AML)- Future Perspectives and Conclusion
Acute Myeloid Leukemia (AML) Analyst Views
Appendix
List of Tables [12]
List of Figures [12]
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/wkfor
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.